CD274 and breast cancer: Another study, PANACEA, also demonstrated a pessimistic outcome of the combination of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive breast cancer with an ORR of 15% in PD-L1 positive patients [75].